mRNA

#Biotechnology #mRNA

eTheRNA research agreement with Merck to access mRNA technologies 

eTheRNA immunotherapies has partnered with Merck to investigate the application of eTheRNA’s mRNA design expertise and LNP-delivery platforms to disease areas selected by Merck.  Context   The ongoing pandemic has underlined the capability for mRNA vaccines as a new therapeutic modality. eTheRNA and Merck both recognise… Read More

#News

#Biotechnology #DNA #Drug discovery #mRNA #Synthetic chemistry

From synthetic biology to synthesising DNA: helping advance research 

Evonetix is reimagining biology. Dr Vijay Narayan, Head of Physics, Dr Stuart Crosby, Head of Synthetic Chemistry, and Daniel Bygrave, Principal Software Engineer, offer insight into the technology being developed by the company and its relevance for researchers.  "I have always been intrigued by interdisciplinary environments,’ says Dr Vijay Narayan, Head of Physics, Evonetix. “This is… Read More

#Business & Investment #Editor's Choice #Exclusive Content #Intelligence #News #Trends & Analysis

#Covid booster #Covid variants #Covid-19 #Immunology / Virology & Vaccines #Moderna #mRNA #Omicron

Moderna begins Omicron booster trial and presents durability data 

Moderna has dosed the first participant in a Phase II study of the company’s Omicron-specific booster candidate (mRNA-1273.529). Additionally, Moderna announced the publication of neutralising antibody data against the Omicron variant six months following a booster dose in The New England Journal of Medicine.   The mRNA-1273.529 trial  This extension… Read More

#News #Trending News

#Antigen #Biotechnology #Immunology / Virology & Vaccines #mRNA #RNA #Therapeutics

What’s next for RNA-based medicine post-Covid-19?

Dr Pirkko Muhonen, Senior Field Application Scientist, Nucleic Acid Therapeutics, at Thermo Fisher Scientific, shares what's next for RNA-based medicine post-pandemic with DDW. With SARS-CoV-2 circulating the globe and leading to over five million deaths worldwide1, all eyes are on the critical role messenger RNA (mRNA) vaccines are playing in… Read More

#Covid-19 #Exclusive Content #News #Trends & Analysis

#Covid booster #Covid-19 #FDA #Immunology / Virology & Vaccines #mRNA

Additional dose of Covid-19 vaccine is safe, says US trial 

A study sponsored by the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, suggests that an additional dose of a Covid-19 vaccine is safe in adults who had previously received a full regimen of any of three Covid-19 vaccines granted Emergency Use Authorization… Read More

#News #Trending News

RNA
#CAR-T #Immunology / Virology & Vaccines #mRNA #T-Cells

Vaccine-like mRNA injection can be used to make CAR-T cells 

A study from researchers in the Perelman School of Medicine at the University of Pennsylvania has shown that an experimental immunotherapy can temporarily reprogramme patients’ immune cells to attack a specific target via only a single injection of mRNA, similar to the mRNA-based Covid-19 vaccines.  Context  The researchers, whose… Read More

#News

#Collaboration #Drug development #Immunology / Virology & Vaccines #mRNA

Pfizer and BioNTech develop first mRNA-based shingles vaccine

Pfizer and BioNTech have announced a new research, development and commercialisation collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles (herpes zoster virus, or HZV), which impacts about one in three people in the US during their lifetime.   Why now?  The collaboration… Read More

#News

#Antibodies #Clinical trials #HIV #Immunology / Virology & Vaccines #mRNA

Experimental mRNA HIV vaccine is safe and shows promise in animals 

An experimental HIV vaccine based on mRNA shows promise in mice and non-human primates, according to scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The results The results, published in Nature Medicine, show that the novel vaccine was safe and… Read More

#News

#Covid-19 #Immunology / Virology & Vaccines #Moderna #mRNA

Moderna announces strategy to address Omicron SARS-CoV-2 variant 

Moderna has announced updates to its strategy to address SARS-CoV-2 variants of concern, given the emergence of the B.1.1.529 (Omicron) variant.   What is Omicron?  The recently described Omicron variant includes mutations seen in the Delta variant that are believed to increase transmissibility and mutations seen… Read More

#Covid-19 #News #Trending News

#Drug design #Drug development #Immunology / Virology & Vaccines #mRNA #RNA #Synthetic biology

RNA: a coming-of-age technology for viral vaccines 

Listen to this article on the DDW Podcast: Dr Andy Lane, Commercial Director at The Native Antigen Company, discusses the development of a new generation of vaccine platforms that can be rapidly adapted to novel threats on-demand and at low cost.  Vaccines are one of the most effective healthcare interventions for reducing… Read More

#Business & Investment #Editor's Choice #Exclusive Content #News #Opinion

Handshake
#Collaboration #Drug development #Immunology / Virology & Vaccines #mRNA

BioNet and BIA Separations collaborate to develop mRNA vaccines 

BioNet and BIA Separations, now part of Sartorius, have developed an optimised mRNA manufacturing process.   BIA’s expertise in chromatographic columns for mRNA purification combined with BioNet’s expertise in the product development of genetic vaccines have, since early 2021, enabled both teams to collaborate on the optimisation and upscale of a high-yield… Read More

#News

#Funding #Immunology / Virology & Vaccines #mRNA

£4 million funding raised for rapid vaccine development platform  

Imophoron, the Bristol-based developer of a rapid-response vaccine platform, ADDomer, has secured £4 million in an oversubscribed fundraising round. Frederic Garzoni, CEO and Co-founder of Imophoron, said: “It has now been demonstrated how a pandemic cannot just threaten lives, but our society and economy as we know it. Imophoron is developing its ADDomer vaccine platform… Read More

#News

#Drug development #Drug discovery #Immunology / Virology & Vaccines #mRNA

AstraZeneca collaboration to develop RNA therapeutics  

AstraZeneca has reached an agreement to collaborate with VaxEquity for the discovery, development and commercialisastion of the self-amplifying RNA (saRNA) therapeutics platform developed at Imperial College London.  The strategic, long-term research collaboration aims to optimise and validate VaxEquity’s saRNA platform and apply it to advance novel therapeutic programmes. AstraZeneca will support VaxEquity with research and development funding and should… Read More

#News

#Covid-19 #GlobalData #Immunology / Virology & Vaccines #mRNA

Too many US adults unvaccinated to vaccinate children 

Following the news that Pfizer/BioNTech will apply for authorisation of their Covid-19 vaccine Comirnaty for children ages 5–11 after showing positive initial data from a trial at a lower dose in this age group; Philipp Rosenbaum, Senior Healthcare Analyst at GlobalData, offers his view.   He said: “It will be… Read More

#Covid-19 #News #Trends & Analysis

#Clinical trial #Covid-19 #Immunology / Virology & Vaccines #Moderna #mRNA #Research

Moderna: new clinical data on its Covid-19 vaccine 

New analysis suggests that the Moderna Covid-19 vaccine is highly effective against circulating variants of concern, including in a vaccine effectiveness study conducted in partnership with Kaiser Permanente Southern California (KPSC) and in a separate recent publication by the US Centers for Disease Control and Prevention (CDC).   Additionally, the company shared… Read More

#Covid-19 #News #Trending News